Fasting Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg
NCT ID: NCT00649740
Last Updated: 2024-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2005-11-30
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Applesauce Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg
NCT00649467
Topiramate 25 mg Capsules Under Fasting Conditions
NCT00905164
Bioequivalence Study of Topiramate Tablets 25mg Under Fasting Conditions
NCT00901784
Topiramate 25 mg Capsule Mixed With Applesauce Under Fasting Conditions
NCT00905346
Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg
NCT00648466
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Topiramate Sprinkle Capsules 25 mg
Topiramate Sprinkle Capsules 25 mg
25mg, single dose fasting
2
Topamax® Sprinkle Capsule 25 mg
Topamax® Sprinkle Capsule 25 mg
25mg, single dose fasting
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Topiramate Sprinkle Capsules 25 mg
25mg, single dose fasting
Topamax® Sprinkle Capsule 25 mg
25mg, single dose fasting
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* able to swallow medication
Exclusion Criteria
* history of any significant disease
* use of any prescription or OTC medications within 14 days of start of study
* received any investigational products within 30 days prior to start of study
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mylan Pharmaceuticals Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mylan Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dorian Williams, M.D.
Role: PRINCIPAL_INVESTIGATOR
Kendle International Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kendle International Inc.
Morgantown, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Mylan Pharmaceuticals Inc. - Clinical Trial Results
Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use
Recalls, Market Withdrawals and Safety Alerts
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TOPR-0583
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.